Published October 31, 2025 | Version v1

Beta-Thalassemia Intermedia in Disguise: A Case of Delayed Diagnosis in a Child with Persistent Cytopenias

Description

Aplastic anemia and thalassemia are two distinct hematological disorders that are rarely seen in combination. This report describes the case of a 7-year-old boy initially diagnosed with aplastic anemia based on clinical and bone marrow findings, who was later found to have coexistent beta-thalassemia intermedia. The patient presented with chronic pallor, fatigue, gum bleeding, and growth retardation, along with persistent thrombocytopenia since age two. Despite multiple platelet transfusions, steroids, and splenectomy, there was no sustained improvement. Subsequent marrow biopsy confirmed aplastic anemia, and treatment with oxymetholone and cyclosporine was initiated. Persistent anemia led to hemoglobin electrophoresis, revealing elevated HbF (24.3%) and confirming beta-thalassemia intermedia. After treatment with thalidomide and hydroxyurea, his transfusion requirements markedly decreased, with the last transfusion in March 2024. This case underscores the diagnostic complexity of overlapping hematologic disorders, particularly in regions with high thalassemia prevalence. Early utilization of hemoglobin electrophoresis in unexplained or refractory cytopenias can help avoid misdiagnosis and guide timely, effective treatment.

Files

Files (26.6 kB)

Name Size Download all
md5:76d3b44d86b6b9b497f1dd2905b775dc
26.6 kB Download

Additional details

Related works

Is published in
Journal: 3066-3202 (ISSN)

Dates

Accepted
2025-10-31

References

  • 1. Maluf E, Hamerschlak N, Cavalcanti AB, et al. Incidence and risk factors of aplastic anemia in Latin American countries: the LATIN case-control study. Haematologica. 2009;94(9):1220-1226. doi:10.3324/haematol.2008.002642 PubMed | Crossref | Google Scholar
  • 2. Mary JY, Baumelou E, Guiguet M. Epidemiology of aplastic anemia in France: a prospective multicentric study. The French Cooperative Group for Epidemiological Study of Aplastic Anemia. Blood. 1990;75(8):1646-1653. doi:10.1182/blood.V75.8.1646.1646 Crossref | Google Scholar
  • 3. Montané E, Ibáñez L, Vidal X, et al. Epidemiology of aplastic anemia: a prospective multicenter study. Haematologica. 2008;93(4):518-523. doi:10.3324/haematol.12020 PubMed | Crossref | Google Scholar
  • 4. Tweddle DA, Reid MM. Aplastic anemia in the northern region of England. Acta Paediatr. 1996;85(11):1388-1389. doi:10.1111/j.1651-2227.1996.tb13938.x PubMed | Crossref
  • 5. Vaht K, Göransson M, Carlson K, et al. Incidence and outcome of acquired aplastic anemia: real-world data from patients diagnosed in Sweden from 2000-2011. Haematologica. 2017;102(10):1683-1690. doi:10.3324/haematol.2017.169862 PubMed | Crossref | Google Scholar
  • 6. Issaragrisil S. Epidemiology of aplastic anemia in Thailand. Thai Aplastic Anemia Study Group. Int J Hematol. 1999;70(3):137-140. Epidemiology of aplastic anemia in Thailand. Thai Aplastic Anemia Study Group
  • 7. Kojima S. Aplastic anemia in the Orient. Int J Hematol. 2002;76 Suppl 2:173-174. doi:10.1007/BF03165112 PubMed | Crossref | Google Scholar
  • 8. Yang C, Zhang X. Incidence survey of aplastic anemia in China. Chin Med Sci J. 1991;6(4):203-207. Incidence survey of aplastic anemia in China
  • 9. Brodsky RA, Jones RJ. Aplastic anaemia. Lancet. 2005;365(9471):1647-1656. doi:10.1016/S0140-6736(05)66515-4 PubMed | Crossref | Google Scholar
  • 10. Geppner AC. Aplastic anemia: A person-centered approach to diagnosis and treatment. JAAPA. 2025;38(4):18-27. doi:10.1097/01.JAA.0000000000000195 PubMed | Crossref | Google Scholar
  • 11. Aitken L, Patel R, D'Rozario J, Choi P. Alemtuzumab-induced red cell aplasia and other immune cytopenias: not so 'pure'. Immunotherapy. 2022;14(2):95-99. doi:10.2217/imt-2021-0163 PubMed | Crossref | Google Scholar
  • 12. Liddle GW, Burke HA Jr. Anabolic steroids in clinical medicine. Helv Med Acta. 1960;27:504-513. Anabolic steroids in clinical medicine
  • 13. Galanello R, Origa R. Beta-thalassemia. Orphanet J Rare Dis. 2010;5:11. doi:10.1186/1750-1172-5-11 PubMed | Crossref | Google Scholar
  • 14. Flint J, Harding RM, Boyce AJ, Clegg JB. The population genetics of the haemoglobinopathies. Baillieres Clin Haematol. 1998;11(1):1-51. doi:10.1016/s0950-3536(98)80069-3 PubMed | Crossref | Google Scholar
  • 15. Bajwa H, Basit H. Thalassemia. eBook. StatPearls Publishing; 2025. Thalassemia
  • 16. Hajjar FM, Pearson HA. Pharmacologic treatment of thalassemia intermedia with hydroxyurea. J Pediatr. 1994;125(3):490-492. doi:10.1016/s0022-3476(05)83304-9 PubMed | Crossref | Google Scholar
  • 17. Taher A, Isma'eel H, Cappellini MD. Thalassemia intermedia: revisited. Blood Cells Mol Dis. 2006;37(1):12-20. doi:10.1016/j.bcmd.2006.04.005 PubMed | Crossref | Google Scholar
  • 18. Fozza C, Pardini S, Giannico DB, et al. Dramatic erythroid response to low-dose thalidomide in two patients with transfusion independent thalassemia and severe post-transfusional alloimmune hemolysis. Am J Hematol. 2015;90(7):E141. doi:10.1002/ajh.24030 PubMed | Crossref | Google Scholar